Skip to main content
Clinical Trials/NCT05136417
NCT05136417
Completed
Not Applicable

Safety and Feasibility of Intra-Cardiac Echocardiography in Guiding Left Atrial Appendage Occlusion With the Watchman Device: The ICE WATCHMAN Study

Mayo Clinic2 sites in 1 country100 target enrollmentJanuary 4, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Left Atrial Appendage Occlusion
Sponsor
Mayo Clinic
Enrollment
100
Locations
2
Primary Endpoint
Successful Implantation of WATCHMAN FLX Device
Status
Completed
Last Updated
last year

Overview

Brief Summary

The purpose of this research is to to assess the feasibility and safety of left atrial appendage (LAA) occlusion with the WATCHMAN FLX™ device using a standardized intra-procedural intracardiac echocardiography (ICE) protocol under moderate sedation for procedural guidance.

Registry
clinicaltrials.gov
Start Date
January 4, 2022
End Date
December 15, 2023
Last Updated
last year
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Mohamad Adnan Alkhouli

Principal Investigator

Mayo Clinic

Eligibility Criteria

Inclusion Criteria

  • The patients is eligible to undergo WATCHMAN device implant procedure.
  • The patient is eligible for short term anticoagulation therapy.
  • Ability to tolerate the procedure without the need for general anesthesia as assessed by the treating physician(s).
  • Ability to give informed consent for the procedure.
  • The patient is able and willing to undergo the procedure under moderate sedation.
  • The patient is able and willing to return for required 45-day transesophageal echocardiogram (TEE).

Exclusion Criteria

  • Patient has contraindication for short term anticoagulation.
  • The patient has history of a hypercoagulable state per medical record documentation.
  • Pregnancy or planning to get pregnant during the investigation.

Outcomes

Primary Outcomes

Successful Implantation of WATCHMAN FLX Device

Time Frame: 45 days post procedure

Number of participants with a successfully implanted WATCHMAN FLX device. Implant success is defined as confirmation of the device-specified release PASS (Position, Anchor, Size, Seal) criteria, successful device release, and adequate seal (defined as a residual leak \<5 mm) as assessed by a core lab interpretation of the transesophageal echocardiogram (TEE) 45 days post-implant.

Major Complications

Time Frame: up to 7 days post procedure

Number of participants who experience major complications defined as major bleeding (intracranial bleeding, or bleeding requiring blood transfusion), pericardial effusion requiring pericardiocentesis or surgery, device embolization, procedural-related stroke, or procedural related death).

Secondary Outcomes

  • Procedure Conversion to General Anesthesia(baseline)
  • Iatrogenic Atrial Septal Defect(45 days post procedure)

Study Sites (2)

Loading locations...

Similar Trials